Although CD73 expression had been observed on some tumors, such as melanomas and prostate cancers, and tumor-infiltrating leukocytes (TILs), especially regulatory T cells (Tregs)2,7,10–12, experimental model systems using Cd73null mice clearly suggest a crucial contribution of host CD73 activity in the non-hematopoietic compartment to the observed immunosuppression12–14. Here, NT5E is linked to prostate cancer.